Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma

References

• Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66:1–79. doi:10.1124/pr.113.007724
   PubMed Web of Science ®Google Scholar
• Haraldsen G, Rot A. Coy decoy with a new ploy: interceptor controls the levels of homeostatic chemokines. Eur J Immunol. 2006;36:1659–1661. doi:10.1002/eji.200636327
   PubMed Web of Science ®Google Scholar
• Wurth R, Bajetto A, Harrison JK, et al. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci. 2014;8:144. doi:10.3389/fncel.2014.00052
   PubMed Web of Science ®Google Scholar
• Rostène W, Guyon A, Kular L, et al. Chemokines and chemokine receptors: new actors in neuroendocrine regulations. Front Neuroendocrinol. 2011;32:10–24. doi:10.1016/j.yfrne.2010.07.001
   PubMed Web of Science ®Google Scholar
• Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009;3:243–249. doi:10.4161/cam.3.3.8260
   PubMed Web of Science ®Google Scholar
• Yu L, Cecil J, Peng S-B, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 2006;374:174–179. doi:10.1016/j.gene.2006.02.001
   PubMed Web of Science ®Google Scholar
• Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998;95:9448–9453.
   PubMed Web of Science ®Google Scholar
• Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595–599. doi:10.1038/31269
   PubMed Web of Science ®Google Scholar
• Reiss K, Mentlein R, Sievers J, et al. Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience. 2002;115:295–305.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med. 2007;13:72–81. doi:10.1016/j.molmed.2006.12.003
   PubMed Web of Science ®Google Scholar
• Sierro F, Biben C, Martínez-Muñoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A. 2007;104:14759–14764. doi:10.1073/pnas.0702229104
   PubMed Web of Science ®Google Scholar
• Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203:2201–2213. doi:10.1084/jem.20052144
   PubMed Web of Science ®Google Scholar
• Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998;187:2009–2021.
   PubMed Web of Science ®Google Scholar
• Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 2003;63:1969–1974.
   PubMed Web of Science ®Google Scholar
• Massa A, Casagrande S, Bajetto A, et al. SDF-1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent, cytosolic tyrosine kinase Pyk2. Ann N Y Acad Sci. 2006;1090:385–398. doi:10.1196/annals.1378.042
   PubMed Web of Science ®Google Scholar
• Cheng ZJ, Zhao J, Sun Y, et al. Beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem. 2000;275:2479–2485.
   PubMed Web of Science ®Google Scholar
• Sun Y, Cheng Z, Ma L, et al. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277:49212–49219. doi:10.1074/jbc.M207294200
   PubMed Web of Science ®Google Scholar
• Levoye A, Balabanian K, Baleux F, et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009;113:6085–6093. doi:10.1182/blood-2008-12-196618
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Grabovsky V, Pasvolsky R, et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol. 2008;84:1130–1140. doi:10.1189/jlb.0208088
   PubMed Web of Science ®Google Scholar
• Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci U S A. 2010;107:628–632. doi:10.1073/pnas.0912852107
   PubMed Web of Science ®Google Scholar
• Berahovich RD, Zabel BA, Penfold MET, et al. CXCR7 protein is not expressed on human or mouse leukocytes. J Immunol. 2010;185:5130–5139. doi:10.4049/jimmunol.1001660
   PubMed Web of Science ®Google Scholar
• Boldajipour B, Mahabaleshwar H, Kardash E, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell. 2008;132:463–473. doi:10.1016/j.cell.2007.12.034
   PubMed Web of Science ®Google Scholar
• Naumann U, Cameroni E, Pruenster M, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One. 2010;5:e9175. doi:10.1371/journal.pone.0009175
   PubMed Web of Science ®Google Scholar
• Décaillot FM, Kazmi MA, Lin Y, et al. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011;286:32188–32197. doi:10.1074/jbc.M111.277038
   PubMed Web of Science ®Google Scholar
• Bajetto A, Barbieri F, Dorcaratto A, et al. Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem Int. 2006;49:423–432. doi:10.1016/j.neuint.2006.03.003
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100:13513–13518. doi:10.1073/pnas.2235846100
   PubMed Web of Science ®Google Scholar
• Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56. doi:10.1038/35065016
   PubMed Web of Science ®Google Scholar
• Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003;63:3833–3839.
   PubMed Web of Science ®Google Scholar
• Barbieri F, Bajetto A, Stumm R, et al. Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res. 2008;14:5022–5032. doi:10.1158/1078-0432.CCR-07-4717
   PubMed Web of Science ®Google Scholar
• Würth R, Barbieri F, Bajetto A, et al. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature. J Neuroimmunol. 2011;234:115–123. doi:10.1016/j.jneuroim.2011.01.006
   PubMed Web of Science ®Google Scholar
• Bajetto A, Barbieri F, Pattarozzi A, et al. CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro. Neuro Oncol. 2007;9:3–11. doi:10.1215/15228517-2006-023
   PubMed Web of Science ®Google Scholar
• Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A. 2007;104:15735–15740. doi:10.1073/pnas.0610444104
   PubMed Web of Science ®Google Scholar
• Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283–4294. doi:10.1074/jbc.M707465200
   PubMed Web of Science ®Google Scholar
• Merino JJ, Bellver-Landete V, Oset-Gasque MJ, et al. CXCR4/CXCR7 molecular involvement in neuronal and neural progenitor migration: focus in CNS repair. J Cell Physiol. 2015;230:27–42. doi:10.1002/jcp.24695
   PubMed Web of Science ®Google Scholar
• Nagasawa T. CXCL12/SDF-1 and CXCR4. Front Immunol. 2015;6:301. doi:10.3389/fimmu.2015.00301
   PubMed Web of Science ®Google Scholar
• Hu Y, Li S. Survival regulation of leukemia stem cells. Cell Mol Life Sci. 2016;73:1039–1050. doi:10.1007/s00018-015-2108-7
   PubMed Web of Science ®Google Scholar
• Khan MI, Czarnecka AM, Helbrecht I, et al. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther. 2015;6:178. doi:10.1186/s13287-015-0177-z
   PubMed Web of Science ®Google Scholar
• Heiler S, Wang Z, Zöller M. Pancreatic cancer stem cell markers and exosomes - the incentive push. World J Gastroenterol. 2016;22:5971–6007. doi:10.3748/wjg.v22.i26.5971
   PubMed Web of Science ®Google Scholar
• Wurth R, Barbieri F, Pattarozzi A, et al. Phenotypical and pharmacological characterization of stem-like cells in human pituitary adenomas. Mol Neurobiol. 2016. doi:10.1007/s12035-016-0025-x. [Epub ahead of print].
   PubMedGoogle Scholar
• Gatti M, Pattarozzi A, Bajetto A, et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013;314:209–220. doi:10.1016/j.tox.2013.10.003
   PubMed Web of Science ®Google Scholar
• de Nigris F, Schiano C, Infante T, et al. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012;7:251–264.
   PubMed Web of Science ®Google Scholar
• Choi W, Yang Y, Xu Y, et al. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem. 2014;14:1574–1589.
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003;2:581–587. doi:10.1038/nrd1134
   PubMed Web of Science ®Google Scholar
• Mosley CA, Wilson LJ, Wiseman JM, et al. Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin Ther Pat. 2009;19:23–38. doi:10.1517/13543770802553483
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:4767–4773. doi:10.1200/JCO.2008.20.7209
   PubMed Web of Science ®Google Scholar
• Kalatskaya I, Berchiche YA, Gravel S, et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009;75:1240–1247. doi:10.1124/mol.108.053389
   PubMed Web of Science ®Google Scholar
• Redjal N, Chan JA, Segal RA, et al. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12:6765–6771. doi:10.1158/1078-0432.CCR-06-1372
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, De Clercq E, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005;70:752–761. doi:10.1016/j.bcp.2005.05.035
   PubMed Web of Science ®Google Scholar
• Liang Z, Zhan W, Zhu A, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7:e34038. doi:10.1371/journal.pone.0034038
   PubMed Web of Science ®Google Scholar
• Mosi RM, Anastassova V, Cox J, et al. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol. 2012;83:472–479. doi:10.1016/j.bcp.2011.11.020
   PubMed Web of Science ®Google Scholar
• Moyle G, DeJesus E, Boffito M, et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis. 2009;48:798–805. doi:10.1086/597097
   PubMed Web of Science ®Google Scholar
• Hsu W-T, Jui H-Y, Huang Y-H, et al. CXCR4 antagonist TG-0054 mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction. Cell Transplant. 2015;24:1313–1328. doi:10.3727/096368914X681739
   PubMed Web of Science ®Google Scholar
• Vitale RM, Gatti M, Carbone M, et al. Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity. ACS Chem Biol. 2013;8:2762–2770. doi:10.1021/cb400521b
   PubMed Web of Science ®Google Scholar
• Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998;253:877–882. doi:10.1006/bbrc.1998.9871
   PubMed Web of Science ®Google Scholar
• Zhang W-B, Navenot J-M, Haribabu B, et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 2002;277:24515–24521. doi:10.1074/jbc.M200889200
   PubMed Web of Science ®Google Scholar
• Tamamura H, Omagari A, Hiramatsu K, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001;11:1897–1902.
   PubMed Web of Science ®Google Scholar
• Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004;3:29–37.
   PubMed Web of Science ®Google Scholar
• Gravel S, Malouf C, Boulais PE, et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem. 2010;285:37939–37943. doi:10.1074/jbc.C110.147470
   PubMed Web of Science ®Google Scholar
• Peled A, Abraham M, Avivi I, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20:469–479. doi:10.1158/1078-0432.CCR-13-1302
   PubMed Web of Science ®Google Scholar
• Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011;39:282–292. doi:10.1016/j.exphem.2010.11.010
   PubMed Web of Science ®Google Scholar
• Kawatkar SP, Yan M, Gevariya H, et al. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp Biol Med (Maywood). 2011;236:844–850. doi:10.1258/ebm.2011.010345
   PubMed Web of Science ®Google Scholar
• Galsky MD, Vogelzang NJ, Conkling P, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20:3581–3588. doi:10.1158/1078-0432.CCR-13-2686
   PubMed Web of Science ®Google Scholar
• Cho B-S, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126:222–232. doi:10.1182/blood-2015-02-628677
   PubMed Web of Science ®Google Scholar
• Robinson JA, Demarco S, Gombert F, et al. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008;13:944–951. doi:10.1016/j.drudis.2008.07.008
   PubMed Web of Science ®Google Scholar
• Karpova D, Dauber K, Spohn G, et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia. 2013;27:2322–2331. doi:10.1038/leu.2013.266
   PubMed Web of Science ®Google Scholar
• Faber A, Roderburg C, Wein F, et al. The many facets of SDF-1α, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 2007;2007:1–10. doi:10.1155/2007/26065
   Google Scholar
• Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201–211. doi:10.1007/s10585-007-9133-3
   PubMed Web of Science ®Google Scholar
• Kwong J, Kulbe H, Wong D, et al. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther. 2009;8:1893–1905. doi:10.1158/1535-7163.MCT-08-0966
   PubMed Web of Science ®Google Scholar
• Li X, Kuang Y, Huang X, et al. Preparation and characterization of a new monoclonal antibody against CXCR4 using lentivirus vector. Int Immunopharmacol. 2016;36:100–105. doi:10.1016/j.intimp.2016.04.020
   PubMed Web of Science ®Google Scholar
• Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–366. doi:10.1158/1078-0432.CCR-12-2333
   PubMed Web of Science ®Google Scholar
• Peng S-B, Zhang X, Paul D, Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic malignancies. PLoS One. 2016;11:e0150585. doi:10.1371/journal.pone.0150585
   PubMedGoogle Scholar
• Broussas M, Boute N, Akla B, et al. A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells. Mol Cancer Ther. 2016;15:1890–1899. doi:10.1158/1535-7163.MCT-16-0041
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107:20565–20570. doi:10.1073/pnas.1012865107
   PubMed Web of Science ®Google Scholar
• Griffiths K, Dolezal O, Cao B, et al. i-bodies, human single domain antibodies that antagonize chemokine receptor CXCR4. J Biol Chem. 2016;291:12641–12657. doi:10.1074/jbc.M116.721050
   PubMed Web of Science ®Google Scholar
• Zhong C, Wang J, Li B, et al. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res. 2013;19:4433–4445. doi:10.1158/1078-0432.CCR-13-0943
   PubMed Web of Science ®Google Scholar
• Maussang D, Mujić-Delić A, Descamps FJ, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem. 2013;288:29562–29572. doi:10.1074/jbc.M113.498436
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Zboralski D, Maasch C, et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014;123:1032–1039. doi:10.1182/blood-2013-03-493924
   PubMed Web of Science ®Google Scholar
• Spinello I, Quaranta MT, Riccioni R, et al. MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer J. 2011;1:e26. doi:10.1038/bcj.2011.24
   PubMed Web of Science ®Google Scholar
• Schepers K, Campbell TB, Passegué E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254–267. doi:10.1016/j.stem.2015.02.014
   PubMed Web of Science ®Google Scholar
• Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208:421–428. doi:10.1084/jem.20110132
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol. 2008;15:49–58. doi:10.1097/MOH.0b013e3282f29012
   PubMed Web of Science ®Google Scholar
• Greenbaum A, Hsu Y-MS, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495:227–230. doi:10.1038/nature11926
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–599. doi:10.1200/JCO.2010.31.0904
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10:96–103. doi:10.1007/s11899-015-0253-6
   PubMed Web of Science ®Google Scholar
• Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861–1865. doi:10.1126/science.1164390
   PubMed Web of Science ®Google Scholar
• Rouault-Pierre K, Lopez-Onieva L, Foster K, et al. HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell. 2013;13:549–563. doi:10.1016/j.stem.2013.08.011
   PubMed Web of Science ®Google Scholar
• Fei F, Stoddart S, Müschen M, et al. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 2010;24:813–820. doi:10.1038/leu.2009.302
   PubMed Web of Science ®Google Scholar
• Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7:48–58. doi:10.1158/1535-7163.MCT-07-0042
   PubMed Web of Science ®Google Scholar
• Beider K, Darash-Yahana M, Blaier O, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014;13:1155–1169. doi:10.1158/1535-7163.MCT-13-0410
   PubMed Web of Science ®Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43–52. doi:10.1038/leu.2008.299
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Lee S-Y, Kim D-Y, et al. Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells. Blood Res. 2015;50:218–226. doi:10.5045/br.2015.50.4.218
   PubMedGoogle Scholar
• Pui C-H, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29:386–391. doi:10.1200/JCO.2010.32.0325
   PubMed Web of Science ®Google Scholar
• de Bock CE, Cools J. T-ALL: home is where the CXCL12 Is. Cancer Cell. 2015;27:745–746. doi:10.1016/j.ccell.2015.05.011
   PubMed Web of Science ®Google Scholar
• Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–553.
   PubMed Web of Science ®Google Scholar
• Pitt LA, Tikhonova AN, Hu H, et al. CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell. 2015;27:755–768. doi:10.1016/j.ccell.2015.05.002
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Yu M, Lim M, et al. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011;25:1314–1323. doi:10.1038/leu.2011.76
   PubMed Web of Science ®Google Scholar
• Sison EAR, Magoon D, Li L, et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 2014;5:8947–8958. doi:10.18632/oncotarget.2407
   PubMed Web of Science ®Google Scholar
• Randhawa S, Cho BS, Ghosh D, et al. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016;174:425–436. doi:10.1111/bjh.2016.174.issue-3
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714–726. doi:10.1016/j.cell.2013.01.019
   PubMed Web of Science ®Google Scholar
• Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71–81. doi:10.1016/j.semcancer.2013.08.011
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2012;97:608–615. doi:10.3324/haematol.2011.052779
   PubMed Web of Science ®Google Scholar
• Chen -S-S, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833–843. doi:10.1038/leu.2015.316
   PubMed Web of Science ®Google Scholar
• Rosich L, Saborit-Villarroya I, López-Guerra M, et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica. 2013;98:1739–1747. doi:10.3324/haematol.2013.088849
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau J-F, O’Hayre M, et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011;117:882–889. doi:10.1182/blood-2010-04-282400
   PubMed Web of Science ®Google Scholar
• Giannoni P, Scaglione S, Quarto R, et al. An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica. 2011;96:1015–1023. doi:10.3324/haematol.2010.029736
   PubMed Web of Science ®Google Scholar
• Kashyap MK, Kumar D, Jones H, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016;7:2809–2822. doi:10.18632/oncotarget.6465
   PubMed Web of Science ®Google Scholar
• Short NJ, Ravandi F. Acute myeloid leukemia: past, present, and prospects for the future. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S25–S29. doi:10.1016/j.clml.2016.02.007
   PubMed Web of Science ®Google Scholar
• Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3:34–39. doi:10.7150/thno.5150
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92:332–341.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam H, Bruserud OA. Subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Front Immunol. 2016;7:205. doi:10.3389/fimmu.2016.00177
   PubMed Web of Science ®Google Scholar
• Kittang AO, Hatfield K, Sand K, et al. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol. 2010;341:149–172. doi:10.1007/82_2010_25
   PubMed Web of Science ®Google Scholar
• Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206–6214. doi:10.1182/blood-2008-06-162123
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119:3917–3924. doi:10.1182/blood-2011-10-383406
   PubMed Web of Science ®Google Scholar
• Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–2252. doi:10.1016/S0140-6736(13)61901-7
   PubMed Web of Science ®Google Scholar
• Prebet T, Zeidan A. Trends in clinical investigation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S57–S63. doi:10.1016/j.clml.2016.02.012
   Google Scholar
• Abe-Suzuki S, Kurata M, Abe S, et al. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab Invest. 2014;94:1212–1223. doi:10.1038/labinvest.2014.110
   PubMed Web of Science ®Google Scholar
• Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016;5:e1062208. doi:10.1080/2162402X.2015.1062208
   PubMed Web of Science ®Google Scholar
• Dillmann F, Veldwijk MR, Laufs S, et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma. 2009;50:1676–1686. doi:10.1080/10428190903150847
   PubMed Web of Science ®Google Scholar
• Wada N, Ikeda J, Nojima S, et al. Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma. Lab Invest. 2016;96:517–525. doi:10.1038/labinvest.2016.28
   PubMed Web of Science ®Google Scholar
• Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22:187–199. doi:10.1158/1078-0432.CCR-15-0987
   PubMed Web of Science ®Google Scholar
• Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1253–1261. doi:10.1016/j.bbmt.2008.08.011
   PubMed Web of Science ®Google Scholar
• Reinholdt L, Laursen MB, Schmitz A, et al. The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomark Res. 2016;4:12. doi:10.1186/s40364-016-0067-2
   PubMed Web of Science ®Google Scholar
• Beider K, Ribakovsky E, Abraham M, et al. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 2013;19:3495–3507. doi:10.1158/1078-0432.CCR-12-3015
   PubMed Web of Science ®Google Scholar
• Gupta SK, Pillarisetti K, Thomas RA, et al. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett. 2001;78:29–34.
   PubMed Web of Science ®Google Scholar